0001140361-14-039584.txt : 20141030 0001140361-14-039584.hdr.sgml : 20141030 20141030192730 ACCESSION NUMBER: 0001140361-14-039584 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20141028 FILED AS OF DATE: 20141030 DATE AS OF CHANGE: 20141030 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: OncoMed Pharmaceuticals Inc CENTRAL INDEX KEY: 0001302573 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 383572512 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 800 CHESAPEAKE DRIVE CITY: REDWOOD CITY STATE: CA ZIP: 94063 BUSINESS PHONE: 650-995-8200 MAIL ADDRESS: STREET 1: 800 CHESAPEAKE DRIVE CITY: REDWOOD CITY STATE: CA ZIP: 94063 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: HASTINGS PAUL J CENTRAL INDEX KEY: 0001309702 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35993 FILM NUMBER: 141184512 MAIL ADDRESS: STREET 1: 61 HARTFORD STREET CITY: SAN FRANCISCO STATE: CA ZIP: 94114 4 1 doc1.xml FORM 4 X0306 4 2014-10-28 0 0001302573 OncoMed Pharmaceuticals Inc OMED 0001309702 HASTINGS PAUL J C/O ONCOMED PHARMACEUTICALS, INC. 800 CHESAPEAKE DRIVE REDWOOD CITY CA 94063 1 1 0 0 Chairman & CEO Common Stock 2014-10-28 4 M 0 8384 1.43 A 31615 D Common Stock 2014-10-28 4 S 0 8384 22.0806 D 23231 D Common Stock 2014-10-29 4 M 0 8385 1.43 A 31616 D Common Stock 2014-10-29 4 S 0 8385 21.8984 D 23231 D Common Stock 324840 I See Footnote Stock Option (Right to Buy) 1.43 2014-10-28 4 M 0 8384 0.00 D 2017-01-11 Common Stock 8384 51123 D Stock Option (RIght to Buy) 1.43 2014-10-29 4 M 0 8385 0.00 D 2017-01-11 Common Stock 8385 42738 D Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 22, 2014. Includes 22,500 restricted stock units. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) restricted stock unit. Includes 731 shares acquired under the Issuer's Employee Stock Purchase Plan on August 29, 2014 This transaction was executed in multiple trades in prices ranging from $21.79 to $22.37, inclusive. The price reported in Column 4 above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. This transaction was executed in multiple trades in prices ranging from $21.31 to $22.15, inclusive. The price reported in Column 4 above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. The shares are held by Paul J. Hastings & Steve N. De Jong, Trustors and/or TTEES, The Hastings-De Jong Lv Tr DTD May 1, 2012. The option is fully vested and exercisable, subject to an annual limitation of 175,438 shares that can be issued to a single grantee upon the exercise of awards under the Issuer's 2004 Stock Incentive Plan. /s/ Alicia J. Hager, Attorney-in-Fact for Paul J. Hastings 2014-10-30